Faisal Khurshid
Stock Analyst at Leerink Partners
(4.16)
# 493
Out of 4,981 analysts
23
Total ratings
61.11%
Success rate
14.58%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $1.98 | +1.01% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $97.92 | +4.17% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $4.61 | +8.46% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $1.24 | -19.35% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $16.20 | +177.78% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.20 | +73.91% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.65 | +21.21% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $5.26 | +204.18% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $46.20 | +29.87% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $98.73 | -18.97% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $2.02 | +642.57% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $9.75 | -28.21% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.13 | +178.98% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $32.36 | -25.83% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.32 | +430.30% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.42 | +47.60% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.85 | +486.85% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $6.83 | +61.05% | 1 | Mar 21, 2023 |
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $1.98
Upside: +1.01%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $97.92
Upside: +4.17%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $4.61
Upside: +8.46%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $1.24
Upside: -19.35%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $16.20
Upside: +177.78%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.20
Upside: +73.91%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.65
Upside: +21.21%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $5.26
Upside: +204.18%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $46.20
Upside: +29.87%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $98.73
Upside: -18.97%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $2.02
Upside: +642.57%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $9.75
Upside: -28.21%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.13
Upside: +178.98%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $32.36
Upside: -25.83%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.32
Upside: +430.30%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.42
Upside: +47.60%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.85
Upside: +486.85%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $6.83
Upside: +61.05%